Gilead 1Q Revenues: $6.4 billion (+16%) 1Q Earnings: $1.7 billion (+11%) Comments: Growth in the quarter was primarily due to Veklury (remdesivir) sales, Cell Therapy growth with Yescarta and the U.S. launch of Tecartus in 3Q20, the first full quarter recognition of Trodelvy sales, and Hepatitis B virus (HBV) growth with Vemlidy, offset by loss of exclusivity of Truvada and tenofovir disoproxil fumarate 300 mg (TDF) and Atripla in the U.S. and COVID-19 pandemic-related impacts in both HIV and...